Natera stock: Incyte trial puts Signatera at center of enrollment

Published on 11/13/2026 at 16:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera stock gains a new oncology catalyst as Incyte uses Signatera in a Phase II colorectal cancer trial. The assay will help guide enrollment.

Signatera moves deeper into trial design

Natera and Incyte are using Signatera to support patient selection and treatment assessment in a Phase II colorectal cancer study.
The collaboration gives investors a new indicator of how Natera is positioning its oncology assay within treatment decisions.
Follow-on expansion into a larger trial or partnership would be the next commercial signal to watch.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera and Incyte are collaborating on a Phase II colorectal cancer immunotherapy trial that places Natera's Signatera assay at the center of patient selection and treatment assessment. Simply Wall St reported the development on Friday, November 13, 2026.

Signatera takes a broader trial role

The study will use Signatera minimal residual disease testing as both a primary and secondary endpoint. Results are also planned to guide enrollment, giving the assay a direct role in identifying patients and measuring the treatment's impact.

For Natera, the collaboration extends Signatera beyond a test ordered during routine oncology care. The arrangement places the assay inside a clinical development program, where its results can influence trial design and treatment decisions.

Leadership continuity remains in focus

The new collaboration comes after Solomon Moshkevich became Natera's chief executive. Simply Wall St linked the development to the company's continuing focus on Signatera, oncology expansion and clinical-trial work rather than a change in strategic direction.

The next investor signal would be a broader partnership or a later-stage study that continues to use Signatera for patient selection and endpoints. Such a step would provide more evidence that the collaboration is developing into a commercial opportunity.